Upgrade to SI Premium - Free Trial

Tango Therapeutics, Inc (TNGX)

24.39 +0.61 (2.57%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 3, 2026 4:05 PM - StreetInsider Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference September 1, 2026 7:00 AM - StreetInsider Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright August 18, 2026 6:39 AM - StreetInsider Tango Therapeutics Inc. (TNGX) Reiterated at Buy by Stifel: 3 Catalysts by YE26 August 17, 2026 7:49 AM - StreetInsider Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l. August 14, 2026 4:49 PM - SEC Filing Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC August 14, 2026 4:20 PM - SEC Filing Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC August 14, 2026 2:12 PM - SEC Filing Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP August 14, 2026 11:05 AM - SEC Filing Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C. August 14, 2026 8:24 AM - SEC Filing Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P. August 12, 2026 12:02 PM - SEC Filing Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim August 12, 2026 6:53 AM - StreetInsider Form 8-K Tango Therapeutics, Inc. For: Aug 11 August 11, 2026 5:13 PM - SEC Filing Form 424B5 Tango Therapeutics, Inc. August 11, 2026 5:11 PM - SEC Filing NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float August 11, 2026 11:01 AM - StreetInsider Tango Therapeutics, Inc. (TNGX) Misses Q2 EPS by 5c August 11, 2026 7:27 AM - StreetInsider Form 8-K Tango Therapeutics, Inc. For: Aug 11 August 11, 2026 7:21 AM - SEC Filing Form 10-Q Tango Therapeutics, Inc. For: Jun 30 August 11, 2026 7:13 AM - SEC Filing Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights August 11, 2026 7:00 AM - StreetInsider Form 8-K/A Tango Therapeutics, Inc. For: Jul 31 August 7, 2026 6:42 AM - SEC Filing Tango Therapeutics Announces Executive Chair Transition August 6, 2026 6:24 PM - Globe NewsWire Form 8-K Tango Therapeutics, Inc. For: Jul 31 August 6, 2026 5:30 PM - SEC Filing Form 4 Tango Therapeutics, Inc. For: Aug 03 Filed by: Crystal Adam August 5, 2026 4:01 PM - SEC Filing Form 144 Tango Therapeutics, Inc. Filed by: Crystal Adam August 3, 2026 4:47 PM - SEC Filing Tango Therapeutics Inc. (TNGX) PT Raised to $40 at Mizuho July 17, 2026 6:34 AM - StreetInsider JPMorgan Starts Tango Therapeutics Inc. (TNGX) at Overweight July 15, 2026 3:01 AM - StreetInsider Form 4 Tango Therapeutics, Inc. For: Jul 01 Filed by: Crystal Adam July 2, 2026 7:24 PM - SEC Filing Tango Therapeutics Inc. (TNGX) PT Raised to $46 at Canaccord June 29, 2026 4:06 AM - StreetInsider Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy June 25, 2026 4:03 PM - StreetInsider Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert June 23, 2026 6:11 PM - SEC Filing Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert June 23, 2026 6:04 PM - SEC Filing Form 8-K Tango Therapeutics, Inc. For: Jun 19 June 23, 2026 5:19 PM - SEC Filing Tango Therapeutics adds Robert Azelby to its board of directors June 22, 2026 4:05 PM - StreetInsider Tango Therapeutics Appoints Robert Azelby to Board of Directors June 22, 2026 4:05 PM - StreetInsider Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP June 17, 2026 4:46 PM - SEC Filing Full Article List